WHO Issues Concern Over Severe Shortage of Obesity Jabs

Under 10% of people that would benefit from GLP-1 drugs such as Wegovy are able to get them, states the WHO as it publishes its initial recommendations on the therapies.

Given over a billion individuals worldwide currently obese, it is calling for broader and more equitable access to GLP-1 medication.

Based on projections, more than two billion will be obese by 2030 unless action is taken.

"The new guidelines recognises that excess weight is a long-term condition that can be treated with holistic and continuous support," said its chief Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and distribution challenges are major hurdles to universal availability to the jabs that can assist patients in reducing considerable weight, explains the agency.

Skinny Jab Shortage

Even in the present most favorable case, the production of GLP-1 therapies might only reach about 100 million people – fewer than 10% of the global need, according to the health organization.

The recommendation urges nations and manufacturers to widen access, by measures like patent sharing.

The intellectual property rights on the active ingredient – the core component of Novo Nordisk's Wegovy – is scheduled to end in several countries in 2026.

The Way Obesity Injections Function

GLP-1 drugs replicate a body's own hormone to delay gastric emptying, suppress the appetite and boost feelings of fullness so individuals eat less.

Individuals typically see weight reduction after several weeks of beginning the weekly injections.

Studies indicates patients may put most of the weight back on a year later of stopping the drug, because their typical food cravings return.

Being above a healthy weight elevates your chance for contracting diseases, such as diabetes, heart disease, stroke, and certain cancers.

Obesity impacts individuals in all nations and was linked to millions of deaths worldwide in 2024, as per the WHO.